Drugs / Coagulation Factor VIII
Trials 1 · a red edge is where a trial was stopped
20162017201820192020202120222023202420252026
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|
|
Phase 3
|
NCT05662319 Background |
Feb 2023 → Mar 2027 expected |
hemophilia |
Sanofi |
Active not recruiting
|
No outcome recorded
|
Evidence & citations 3 cited values
Every value below carries the sentence it was read from.
2 sources stand behind the page.
| Field | Value | Cited text |
|---|
| Known as |
Coagulation Factor VIII |
“Coagulation factor VIII (ATC code: B02BD02)” NCT05662319 ↗1NCT03598725 ↗ |
| Modality |
Protein / enzyme biologic |
“Domastic plasma derived factor FVIII (with intermidiate vWF)” NCT03598725 ↗
|
| Route |
Intravenous |
“Route of administration: Intravenous (IV)” NCT05662319 ↗
|